bKIT™ Virus Finder COVID-19 Saliva

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) is a strain of coronavirus that causes Coronavirus Disease 2019 (COVID-19), the respiratory illness responsible for the ongoing COVID-19 pandemic. SARS‑CoV‑2 undergoes frequent recombination of the positive-sense single-stranded RNA (+ssRNA) about 30,000 bases long that encodes several proteins among which the spike, envelope, membrane, and nucleocapsid structural proteins.

Use

The HYRIS bKIT™ Virus Finder COVID-19 Saliva is a CE-IVD real-time RT-PCR assay intended to be used for the in vitro diagnostic qualitative detection of SARS-CoV-2 nucleic acid in saliva specimens collected by a healthcare professional from individuals suspected of COVID-19 disease.

Therefore, no sample extraction is mandatory prior to the RT-qPCR. The SARS-CoV-2 RNA detection occurs through specific primers and probe sets for the viral nucleocapsid gene (N gene).

Mix 1:

2019-nCoV_N1: nucleocapsid (N) gene for specific detection of SARS-CoV-2 (FAM)
RPP30: human RNase P as sampling and RT-qPCR control (HEX)

Mix 2:

2019-nCoV_N2: nucleocapsid (N) gene for specific detection of SARS-CoV-2 (FAM)

PRODUCT COMPOSITION

bKTH-SCV2.04-32	Direct Real Time PCR test for SARS-CoV-2 detection in saliva specimens - 32 tests/kit
bKTH-SCV2.04-72	Direct Real Time PCR test for SARS-CoV-2 detection in saliva specimens - 72 tests/kit

RESOURCES

Product Datasheet	Download
Hyris COVID-19 Solutions	Download

FAQ

On which instruments is the assay validated?

bKIT™ Virus Finder COVID-19 Saliva is Intended to be used on Hyris System™, composed by the HYRIS bCUBE™ instrument and HYRIS bAPP™ software.

How many samples can be analysed for each run?

Hyris System™ can process 6 or 16 samples per run, depending on the cartridge format to be used.

Solutions

Disruptive solutions
for different sectors and use cases.

Hyris System™

The first multi-market platform able to deliver real value for the final customer, in a marketplace approach.

Partners

Hyris System™ allows a wide range of operators and researchers to develop their own assays and kits.

About Us

Hyris is a tech-bio company committed to democratise genetics and health insights.

Latest

Hyris signs a distribution agreement with GrowBIGogh

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine